Relay Therapeutics Analyst Ratings
Relay Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/17/2023 | 337.09% | HC Wainwright & Co. | $30 → $33 | Maintains | Buy |
| 08/17/2023 | 297.35% | HC Wainwright & Co. | $32 → $30 | Maintains | Buy |
| 08/09/2023 | 337.09% | Oppenheimer | → $33 | Reiterates | Outperform → Outperform |
| 06/09/2023 | 323.84% | HC Wainwright & Co. | $46 → $32 | Maintains | Buy |
| 05/05/2023 | 217.88% | JMP Securities | $28 → $24 | Maintains | Market Outperform |
| 04/20/2023 | 65.56% | Jefferies | $16 → $12.5 | Upgrades | Underperform → Hold |
| 04/20/2023 | 350.33% | Stifel | $38 → $34 | Maintains | Buy |
| 04/19/2023 | 284.11% | JP Morgan | $42 → $29 | Maintains | Overweight |
| 04/19/2023 | 270.86% | JMP Securities | → $28 | Reiterates | → Market Outperform |
| 04/19/2023 | 284.11% | Raymond James | → $29 | Upgrades | Outperform → Strong Buy |
| 04/19/2023 | 98.68% | Barclays | $23 → $15 | Maintains | Equal-Weight |
| 04/18/2023 | 337.09% | Oppenheimer | → $33 | Maintains | Outperform |
| 04/13/2023 | 284.11% | Raymond James | → $29 | Initiates Coverage On | → Outperform |
| 04/05/2023 | 456.29% | JP Morgan | $45 → $42 | Maintains | Overweight |
| 03/07/2023 | 509.27% | HC Wainwright & Co. | $43 → $46 | Maintains | Buy |
| 02/03/2023 | 337.09% | Oppenheimer | → $33 | Initiates Coverage On | → Outperform |
| 01/19/2023 | 270.86% | JMP Securities | $38 → $28 | Maintains | Market Outperform |
| 11/07/2022 | 469.54% | HC Wainwright & Co. | $50 → $43 | Maintains | Buy |
| 09/30/2022 | 204.64% | Barclays | → $23 | Initiates Coverage On | → Equal-Weight |
| 09/14/2022 | 403.31% | JMP Securities | $35 → $38 | Maintains | Market Outperform |
| 09/12/2022 | 562.25% | HC Wainwright & Co. | $46 → $50 | Maintains | Buy |
| 09/02/2022 | 429.8% | Stifel | → $40 | Initiates Coverage On | → Buy |
| 08/09/2022 | 509.27% | HC Wainwright & Co. | $47 → $46 | Maintains | Buy |
| 06/06/2022 | 72.19% | Jefferies | → $13 | Initiates Coverage On | → Underperform |
| 05/24/2022 | 456.29% | Goldman Sachs | $49 → $42 | Maintains | Buy |
| 05/10/2022 | 522.52% | HC Wainwright & Co. | $54 → $47 | Maintains | Buy |
| 05/09/2022 | 363.58% | JMP Securities | $50 → $35 | Maintains | Market Outperform |
| 02/01/2022 | 496.03% | Berenberg | → $45 | Initiates Coverage On | → Buy |
| 08/17/2021 | 615.23% | HC Wainwright & Co. | $57 → $54 | Maintains | Buy |
| 07/21/2021 | 562.25% | B of A Securities | → $50 | Initiates Coverage On | → Buy |
| 01/29/2021 | 588.74% | JP Morgan | $36 → $52 | Maintains | Neutral |
| 12/15/2020 | 654.97% | HC Wainwright & Co. | $54 → $57 | Maintains | Buy |
| 12/08/2020 | 774.17% | JMP Securities | → $66 | Initiates Coverage On | → Market Outperform |
| 11/05/2020 | 615.23% | HC Wainwright & Co. | → $54 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 10/17/2023 | 337.09% | HC Wainwright公司 | $30→$33 | 維護 | 買 |
| 2023年08月17日 | 297.35% | HC Wainwright公司 | $32→$30 | 維護 | 買 |
| 08/09/2023 | 337.09% | 奧本海默 | →$33 | 重申 | 跑贏→跑贏大盤 |
| 06/09/2023 | 323.84% | HC Wainwright公司 | $46→$32 | 維護 | 買 |
| 05/05/2023 | 217.88% | JMP證券 | $28→$24 | 維護 | 市場表現強於大盤 |
| 04/20/2023 | 65.56% | 傑富瑞 | $16→$12.5 | 升級 | 表現不佳的→保持 |
| 04/20/2023 | 350.33% | Stifel | $38→$34 | 維護 | 買 |
| 04/19/2023 | 284.11% | 摩根大通 | $42→$29 | 維護 | 超重 |
| 04/19/2023 | 270.86% | JMP證券 | →$28 | 重申 | →市場跑贏大盤 |
| 04/19/2023 | 284.11% | 雷蒙德·詹姆斯 | →$29 | 升級 | 跑贏→強勢買入 |
| 04/19/2023 | 98.68% | 巴克萊 | $23→$15 | 維護 | 等重 |
| 04/18/2023 | 337.09% | 奧本海默 | →$33 | 維護 | 跑贏大盤 |
| 04/13/2023 | 284.11% | 雷蒙德·詹姆斯 | →$29 | 開始承保 | →跑贏大盤 |
| 04/05/2023 | 456.29% | 摩根大通 | $45→$42 | 維護 | 超重 |
| 03/07/2023 | 509.27% | HC Wainwright公司 | $43→$46 | 維護 | 買 |
| 02/03/2023 | 337.09% | 奧本海默 | →$33 | 開始承保 | →跑贏大盤 |
| 2023年1月19日 | 270.86% | JMP證券 | $38→$28 | 維護 | 市場表現強於大盤 |
| 11/07/2022 | 469.54% | HC Wainwright公司 | $50→$43 | 維護 | 買 |
| 09/30/2022 | 204.64% | 巴克萊 | →$23 | 開始承保 | →等重 |
| 09/14/2022 | 403.31% | JMP證券 | $35→$38 | 維護 | 市場表現強於大盤 |
| 09/12/2022 | 562.25% | HC Wainwright公司 | $46→$50 | 維護 | 買 |
| 09/02/2022 | 429.8% | Stifel | →$40 | 開始承保 | →購買 |
| 08/09/2022 | 509.27% | HC Wainwright公司 | $47→$46 | 維護 | 買 |
| 06/06/2022 | 72.19% | 傑富瑞 | →$13 | 開始承保 | →表現不佳 |
| 2022年05月24日 | 456.29% | 高盛 | $49→$42 | 維護 | 買 |
| 2022年05月10日 | 522.52% | HC Wainwright公司 | $54→$47 | 維護 | 買 |
| 05/09/2022 | 363.58% | JMP證券 | $50→$35 | 維護 | 市場表現強於大盤 |
| 02/01/2022 | 496.03% | 貝倫伯格 | →$45 | 開始承保 | →購買 |
| 2021/08/17 | 615.23% | HC Wainwright公司 | $57→$54 | 維護 | 買 |
| 07/21/2021 | 562.25% | B of A證券 | →$50 | 開始承保 | →購買 |
| 2021/01/29 | 588.74% | 摩根大通 | $36→$52 | 維護 | 中性 |
| 12/15/2020 | 654.97% | HC Wainwright公司 | $54→$57 | 維護 | 買 |
| 12/08/2020 | 774.17% | JMP證券 | →$66 | 開始承保 | →市場跑贏大盤 |
| 11/05/2020 | 615.23% | HC Wainwright公司 | →$54 | 開始承保 | →購買 |
What is the target price for Relay Therapeutics (RLAY)?
接力治療(RLAY)的目標價格是多少？
The latest price target for Relay Therapeutics (NASDAQ: RLAY) was reported by HC Wainwright & Co. on October 17, 2023. The analyst firm set a price target for $33.00 expecting RLAY to rise to within 12 months (a possible 337.09% upside). 18 analyst firms have reported ratings in the last year.
HC Wainwright&Co.於2023年10月17日報道了Relay治療公司(納斯達克代碼：RLAY)的最新目標價。這家分析公司將目標價定為33美元，預計RLAY將在12個月內升至(可能上漲337.09%)。去年有18家分析公司公佈了評級。
What is the most recent analyst rating for Relay Therapeutics (RLAY)?
接力治療公司(RLAY)的最新分析師評級是多少？
The latest analyst rating for Relay Therapeutics (NASDAQ: RLAY) was provided by HC Wainwright & Co., and Relay Therapeutics maintained their buy rating.
對Relay治療公司(納斯達克代碼：RLAY)的最新分析師評級由HC Wainwright&Co.提供，Relay治療公司維持其買入評級。
When is the next analyst rating going to be posted or updated for Relay Therapeutics (RLAY)?
下一次分析師對Relay Treeutics(RLAY)的評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Relay Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Relay Therapeutics was filed on October 17, 2023 so you should expect the next rating to be made available sometime around October 17, 2024.
分析師在進行了廣泛的研究後得出股票評級，其中包括查閱公共財務報表，與Relay Treeutics的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Relay治療公司的上一次評級是在2023年10月17日提交的，所以你應該預計下一次評級將在2024年10月17日左右的某個時候提供。
Is the Analyst Rating Relay Therapeutics (RLAY) correct?
分析師對Relay Treeutics(RLAY)的評級正確嗎？
While ratings are subjective and will change, the latest Relay Therapeutics (RLAY) rating was a maintained with a price target of $30.00 to $33.00. The current price Relay Therapeutics (RLAY) is trading at is $7.55, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的接力治療(RLAY)評級保持不變，目標價在30.00美元至33.00美元之間。Relay Treateutics(RLAY)目前的交易價格為7.55美元，超出了分析師的預測範圍。
譯文內容由第三人軟體翻譯。